Mirati Therapeutics Doses First Patient in Phase 2 Study of Mocetinostat in Bladder Cancer Patients with Genetic Alterations of CREBBP and EP300
SAN DIEGO, Jan. 7, 2015 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient has been dosed in a Phase 2 clinical trial designed to evaluate the efficacy, safety and pharmacokinetics of mocetinostat as a treatment for a select group of patients with bladder cancer. The trial will enroll patients whose tumors have mutations or deletions of the CREBBP and/or EP300 genes.
© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.